CSN Login
Members Online: 2

You are here

Looking for experience with ribociclib (Kisqali)

Telephone number: 
Friday, September 29, 2017 - 9:30am
First Name: 
Last Name: 
Announcement removal date: 
Monday, October 30, 2017 - 4:30pm
Have you submitted an announcement request to CSN in the past?: 
Your announcement.: 

My name of MJ DeCoteau and I am the executive director of Rethink Breast Cancer – a Canadian patient group dedicated to building community for young women dealing with breast cancer and providing support and resources to help them live the best quality of life.


We are looking for woman with HR-positive, HER2-negative advanced breast cancer and women who have been treated with ribociclib (Kisqali) to talk about their treatment experience.


The Canadian government will soon be reviewing the use of ribociclib to treat HR-positive, HER2-negative advanced breast cancer in postmenopausal women and Rethink Breast Cancer will be making a submission to ensure that patient voices are represented and considered during the review process.


We would like to speak with women in the United States or other countries about their experience with HR-positive, HER2-negative advanced breast cancer or being treated with ribociclib.


If you are interested in talking about your experiences, we would like to ask you to complete this survey: https://www.surveymonkey.com/r/2C5SNVX


If you would like to speak with us directly about your cancer or treatment experience, you can contact Shawna Rich-Ginsberg at shawna@rethinkbreastcancer.com.


We would also like to invite your family or friends to talk about their experience caring for a patient being treated with ribociclib: https://www.surveymonkey.com/r/2Q7LKFG


Please feel free to resend or repost this message as widely as possible.


Click here if you would like more information about Rethink Breast Cancer or the pan-Canadian Oncology Drug Review.


MJ DeCoteau

Founder + Executive Director

Rethink Breast Cancer

The above research study announcement posted on Cancer Survivors Network is intended to be informational in nature. The American Cancer Society does not warrant or guarantee the accuracy of the information provided and will not oversee or otherwise be involved in the conduct of the actual research study. We recommend that you consult with your health care provider if you have concerns about your health before participating in any research study. Any information you obtain through CSN announcements should not be used as a substitute for consultation with your health care provider.

Web site URL (if applicable): 
Check the appropriate category for your announcement: 
Opportunity to Get Involved (e.g. advocacy, volunteer)
Contact - Email: 
Contact - First name: 
Contact - Last name: 
Contact - Telephone number: 
Subscribe to Comments for "Looking for experience with ribociclib (Kisqali)"